SCHEMBL477481

SCHEMBL477481

C[C@@H](F)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL478047 1.00
SCHEMBL131611 1.00
SCHEMBL7857337 0.75
SCHEMBL18125193 0.73
Alcohol SCHEMBL28131143 0.73
SCHEMBL23009184 0.72
SCHEMBL9405740 0.72
SCHEMBL20288090 0.72
SCHEMBL477958 0.72
SCHEMBL18631414 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111792985-A Fluorine-containing heat transfer fluid and preparation method and application thereof 北京宇极科技发展有限公司 2020-10-20 CN claimed
EP-2860175-B1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF TACURION (US) 2017-11-29 EP claimed
US-9598373-B2 Method for producing 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound and intermediate used in the method TACURION (US) 2017-03-21 US claimed
US-20150141641-A1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE USED IN THE METHOD ASTELLAS PHARMA INC. (JP) 2015-05-21 US claimed
EP-2860175-A1 METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF Astellas Pharma Inc. (JP) 2015-04-15 EP claimed
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 EP disclosed
US-20250074901-A1 NOVEL HETEROARYL COMPOUNDS ANGELINI PHARMA S.P.A. (IT) 2025-03-06 US disclosed
CN-119241481-A Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors 诺华股份有限公司 2025-01-03 CN disclosed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
CN-115298170-B Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors 诺华股份有限公司 2024-09-27 CN disclosed
EP-4433453-A1 NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS Icagen, LLC (US) 2024-09-25 EP disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed
US-20080103327-A1 Industrial production of high purity drug and optical materials intermediates; reacting optically active alpha hydroxycarboxylate derivative with trifluoromethanesulfonyl fluoride in presence of organic base CENTRAL GLASS COMPANY, LIMITED (JP) 2008-05-01 US disclosed
WO-2008046919-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2008-04-24 WO disclosed
US-20080045493-A1 Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-02-21 US disclosed
CN-101111462-A Process for production of fluoro derivative CENTRAL GLASS CO LTD (JP) 2008-01-23 CN disclosed
EP-1842841-A1 PROCESS FOR PRODUCTION OF FLUORO DERIVATIVE Central Glass Company, Limited (JP) 2007-10-10 EP disclosed
EP-1814849-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2007-08-08 EP disclosed
EP-1780194-A1 PROCES FOR PRODUCTION OF OPTICALLY ALPHA-FLUORO-CARBOXYLIC ESTER DERIVATIVES Central Glass Company, Limited (JP) 2007-05-02 EP disclosed
WO-2006040182-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed